Skip to main content
Clinical Trials/NCT02711306
NCT02711306
Completed
Not Applicable

Office of Human Research, Taipei Medical University

Taipei Medical University0 sites36 target enrollmentMay 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome
Sponsor
Taipei Medical University
Enrollment
36
Primary Endpoint
Body Weight
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.

Detailed Description

The KGN diet was composed of well-cooked noodle with 2 g of KGM in a dosage of 200 g/piece twice daily to substitute the daily carbohydrate for 4 weeks, with a 2-week washout period between alternative diets. All 33 subjects received two servings of either GMNs or PNs (400 g) per day, which replaced the main carbohydrate in two daily meals for 4 weeks. After a 2-week washout period, the subjects received the other type of noodle for 4 weeks. The body weight, BMI, waist circumference, fasting blood glucose and lipid profile, as well as serum vitamin A, E, β-carotene and high sensitivity C-reactive protein (hs-CPR) were measured by HPCL.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
March 2014
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults with metabolic syndrome
  • Subjects were considered to have metabolic syndrome if subjects had 3 of the following 5 characteristics:
  • Abdominal obesity (waist circumference \>= 90 cm in men and \>= 80 cm in women)
  • Impaired fasting glucose ( \>= 5.6 mmol/L)
  • Hypertriglyceridemia ( \>= 1.7 mmol/L)
  • Low HDL-C (\< 1.0 mmol/L in men and \< 1.3 mmol/L in women)
  • Increased blood pressure (SBP \>= 130 mmHg and DBP \>= 85 mmHg).

Exclusion Criteria

  • Liver and renal diseases
  • Undergoing statin therapy
  • Pregnancy women
  • Taking antioxidant vitamins supplements

Outcomes

Primary Outcomes

Body Weight

Time Frame: 4 weeks

Body weight by weighting scale (kilogram). Lower scores mean a better outcome in subjects.

Secondary Outcomes

  • Waist Circumference(4 weeks)
  • Glycemic Index(4 weeks)
  • Lipid Index(4 weeks)

Similar Trials